Vivek Ramaswamy Quotes

Australia is already a world leader in dementia research, treatment and care.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

It seems paradoxical that, as medical scientists make huge advances in discovering the mechanisms of common diseases, fewer and fewer innovative drugs are reaching the market.

There's always going to be the need for new medications, better medications.

Over the years, HIV/AIDS activists and their allies have been pioneers in creating new frontiers in the medical establishment. Through their efforts, the FDA drug approval procedures were reformed so promising new therapies could reach desperate patients quicker.

The problem of chemotherapy of bacterial infections could be solved neither by the experimental medical research worker nor by the chemist alone, but only by the two together working in very close cooperation over many years.

Huge sums are invested globally in medical research and development - and with good reason.

I have a particular passion and focus on Alzheimer's and diseases of dementia. There's just so much scientifically that we don't know, and we can know.

Today there are no Alzheimer’s survivors. That means that Alzheimer’s patients can’t speak for themselves. Widespread blood tests could create an army of “pre-Alzheimer’s” patients clamoring for breakthroughs in treatment.

Affordability is critical so that patients have access to medicines. At the same time, it's also important that we have the kind of incentives that allow us to do the kinds of studies that we need to do to go after these diseases like Alzheimer's.

To ensure that America remains the leader in medical innovation, we must reduce the costs of developing life-saving drugs and ensure that there are appropriate economic incentives in place to produce them.

If we can validate our scientific bets in the clinic, if we can bring valuable new treatments to patients that need them, that will be our ultimate measure of success.

To start with, pharma was an industry based on innovation, drug discovery.

When I was a medical student in the 1950s, we practically never spoke about Alzheimer's disease. And why is that so? And that is because people didn't live long enough to have Alzheimer's disease.

Drug discovery is terribly expensive, just to find out how one drug could or could not work and all its side effects.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.

And there are lots of drug companies that are working on cure or medicine.

No matter who you are, what you've accomplished, what your financial situation is - when you're dealing with a parent with Alzheimer's, you yourself feel helpless. The parent can't work, can't live alone, and is totally dependent, like a toddler. As the disease unfolds, you don't know what to expect.

The bottom line is that this author, a practicing neurologist dealing with Alzheimer's disease on a daily basis, believes we need to expand the public awareness that modifiable lifestyle factors have a profound role to play in determining who will or won't get this disease.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

All I ever promised was that I was sure I could develop a new pharmacological agent which might answer a physiological question. Any utility would be implicit in that answer.

The science supporting the relationship between carbohydrates and dementia is quite exciting, as it paves the way for lifestyle changes that can profoundly affect a person's chances of remaining intact, at least from a brain perspective.

I am particularly interested in Alzheimer's disease and have been for some time now.

Alzheimer's is literally killing us, and the only way to fight this 'crime' is through a groundswell of people who continue to raise their voices and funds to ensure it gets the attention it deserves.

Even then, Vanderbilt was the premiere place for clinical pharmacology.